aspirin acetoxymethyl ester | 118247-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: aspirin acetoxymethyl ester
• 英文别名: 2-Acetoxy-benzoic acid acetoxymethyl ester；acetyloxymethyl 2-acetyloxybenzoate
• CAS: 118247-06-6
• 化学式: C₁₂H₁₂O₆
• 分子量: 252.224
• InChiKey: QNGPCPPXGGUHNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  aspirin acetoxymethyl ester 在 10 percent human plasma 作用下， 以 乙腈 为溶剂， 生成 salicylic acid acetoxymethyl ester 、 阿司匹林
  参考文献：
  名称：

  评估阿司匹林的乙醇酰胺酯和其他各种酯类化合物是否为真正的阿司匹林前药。

  摘要：

  合成了一系列乙酰基水杨酸（阿司匹林）的乙醇酰胺，乙醇酸酯，（酰氧基）甲基，烷基和芳基酯，并将其评估为阿司匹林的潜在前药形式。N，N-二取代的乙醇酰胺酯被发现在人血浆中迅速水解，导致形成阿司匹林以及相应的水杨酸酯。这些反过来又迅速水解成水杨酸。在N，N-二甲基-和N，N-二乙基甘醇酰胺酯的情况下，由这些酯形成的最大量的阿司匹林分别为50和55％。用N，N-二甲基-和N，N-二乙基乙醇酰胺酯在血液中获得了相似的结果。未取代的和单取代的乙二酰胺酰胺酯以及大多数其他先前被认为是阿司匹林前体酯的酯已显示出仅水解为相应的水杨酸酯。测定了酯的亲脂性参数和水溶性，并讨论了有利于酯前药水解但以脱乙酰基为代价产生水杨酸酯的结构因素。关于阿司匹林的一些N，N-二取代的乙醇酰胺酯的特性，突出了它们作为潜在的阿司匹林前药的用途。

  DOI：

  10.1021/jm00123a040

文献信息

• [EN] MODIFIED DOUBLE-STRANDED RNA AGENTS<br/>[FR] AGENTS D'ARN DOUBLE BRIN MODIFIÉ
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2016028649A1

  公开（公告）日：2016-02-25

  One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2'-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

  本发明的一个方面涉及能够抑制靶基因表达的双链RNA（dsRNA）试剂。dsRNA试剂的sense链包含至少一个热不稳定核苷酸，并且至少一个该热不稳定核苷酸出现在与antisense链的seed区域（位置2-8）相对的位置上；dsRNA试剂的antisense链包含至少两个修饰核苷酸，这些核苷酸提供的立体体积小于或等于2'-OMe修饰的立体体积，其中这些修饰的核苷酸相隔11个核苷酸长度。该发明的其他方面涉及包含这些dsRNA试剂的药物组合物，适用于治疗用途，并通过给予这些dsRNA试剂的方法来抑制靶基因的表达，例如用于治疗各种疾病条件。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2016142867A1

  公开（公告）日：2016-09-15

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及对抗血管紧张素II型2(AT2)受体的杂环化合物。更具体地，本发明涉及公式(I)所述的化合物，包含它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病中的使用，包括神经病理性疼痛、炎症性疼痛、与神经元过敏性相关的疾病、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成不平衡相关的疾病以及与异常神经再生相关的疾病。
• NEW NO-DONOR ASPIRIN DERIVATIVES
  申请人：Fruttero Roberta

  公开号：US20100210694A1

  公开（公告）日：2010-08-19

  The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.

  本发明涉及一种新的NO供体阿司匹林衍生物，其制备方法和包含它们的药物组合物。
• [EN] EFLORNITHINE PRODRUGS, CONJUGATES AND SALTS, AND METHODS OF USE THEREOF<br/>[FR] PROMÉDICAMENTS D'ÉFLORNITHINE, CONJUGUÉS ET SELS, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：KYPHIA PHARMACEUTICALS INC

  公开号：WO2010056919A2

  公开（公告）日：2010-05-20

  In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a composition of an eflornithine prodrug. In another aspect, the present invention provides a composition of an eflornithine or its derivatives aspirin salt. In another aspect, the present invention provides methods for treating or preventing cancer using the conjugates or salts of eflornithine analogs or eflornithine prodrugs.
• [EN] MACROLIDES AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] MACROLIDES ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：HARVARD COLLEGE

  公开号：WO2014165792A2

  公开（公告）日：2014-10-09

  Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.